Towards third generation matrix metalloproteinase inhibitors for cancer therapy

The failure of matrix metalloproteinase (MMP) inhibitor drug clinical trials in cancer was partly due to the inadvertent inhibition of MMP antitargets that counterbalanced the benefits of MMP target inhibition. We explore how MMP inhibitor drugs might be developed to achieve potent selectivity for v...

Descripción completa

Detalles Bibliográficos
Autores principales: Overall, C M, Kleifeld, O
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2006
Materias:
Minireview
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361222/
https://www.ncbi.nlm.nih.gov/pubmed/16538215
http://dx.doi.org/10.1038/sj.bjc.6603043
_version_ 1782153163191615488
author Overall, C M
Kleifeld, O
author_facet Overall, C M
Kleifeld, O
author_sort Overall, C M
collection PubMed
description The failure of matrix metalloproteinase (MMP) inhibitor drug clinical trials in cancer was partly due to the inadvertent inhibition of MMP antitargets that counterbalanced the benefits of MMP target inhibition. We explore how MMP inhibitor drugs might be developed to achieve potent selectivity for validated MMP targets yet therapeutically spare MMP antitargets that are critical in host protection.
format Text
id pubmed-2361222
institution National Center for Biotechnology Information
language English
publishDate 2006
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-23612222009-09-10 Towards third generation matrix metalloproteinase inhibitors for cancer therapy Overall, C M Kleifeld, O Br J Cancer Minireview The failure of matrix metalloproteinase (MMP) inhibitor drug clinical trials in cancer was partly due to the inadvertent inhibition of MMP antitargets that counterbalanced the benefits of MMP target inhibition. We explore how MMP inhibitor drugs might be developed to achieve potent selectivity for validated MMP targets yet therapeutically spare MMP antitargets that are critical in host protection. Nature Publishing Group 2006-04-10 2006-03-14 /pmc/articles/PMC2361222/ /pubmed/16538215 http://dx.doi.org/10.1038/sj.bjc.6603043 Text en Copyright © 2006 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Minireview
Overall, C M
Kleifeld, O
Towards third generation matrix metalloproteinase inhibitors for cancer therapy
title Towards third generation matrix metalloproteinase inhibitors for cancer therapy
title_full Towards third generation matrix metalloproteinase inhibitors for cancer therapy
title_fullStr Towards third generation matrix metalloproteinase inhibitors for cancer therapy
title_full_unstemmed Towards third generation matrix metalloproteinase inhibitors for cancer therapy
title_short Towards third generation matrix metalloproteinase inhibitors for cancer therapy
title_sort towards third generation matrix metalloproteinase inhibitors for cancer therapy
topic Minireview
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361222/
https://www.ncbi.nlm.nih.gov/pubmed/16538215
http://dx.doi.org/10.1038/sj.bjc.6603043
work_keys_str_mv AT overallcm towardsthirdgenerationmatrixmetalloproteinaseinhibitorsforcancertherapy
AT kleifeldo towardsthirdgenerationmatrixmetalloproteinaseinhibitorsforcancertherapy

Ejemplares similares